# A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

> **NCT04241549** · PHASE1 · COMPLETED · sponsor: **OncoVerity, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Cusatuzumab
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04241549
- **Lead sponsor:** OncoVerity, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-25
- **Primary completion:** 2021-07-19
- **Final completion:** 2021-07-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-08-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04241549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04241549, "A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04241549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*